Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms

Clinical Endocrinology

Volumn 81, Issue 2, 2014, Pages 157-168

  Kaltsas, Gregory ^a   Grozinsky Glasberg, Simona ^b   Alexandraki, Krystallenia I ^a   Thomas, Dimitrios ^a   Tsolakis, Apostolos V ^c   Gross, David ^b   Grossman, Ashley B ^d  

^a UNIVERSITY OF ATHENS   (Greece)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Section of Oncology   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CHROMOGRANIN A; GASTRIN; NETAZEPIDE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; FOLLOW UP; GASTRIC NEUROENDOCRINE NEOPLASM TYPE 1; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; NEUROENDOCRINE TUMOR; NEUROENDOSCOPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; GASTROINTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDY;

GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PROSPECTIVE STUDIES;

EID: 84904285356     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12476     Document Type: Review

References (70)

1. Kaltsas, G.A., Besser, G.M., &, Grossman, A.B., (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews, 25, 458-511.
2. Modlin, I.M., Lye, K.D., &, Kidd, M., (2004) A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? The American Journal Gastroenterology, 99, 23-32.
3. Yao, J.C., Hassan, M., Phan, A., et al,. (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology, 26, 3063-3072.
4. Berge, T., &, Linell, F., (1976) Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathologica et Microbiologica Scandinavica. Section A, Pathology, 84, 322-330.
5. Kidd, M., Modlin, I.M., Eick, G.N., et al,. (2007) Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. American Journal of Physiology. Gastrointestinal and Liver Physiology, 292, G191-G200.
6. Modlin, I.M., Latich, I., Kidd, M., et al,. (2006) Therapeutic options for gastrointestinal carcinoids. Clinical Gastroenterology and Hepatology, 4, 526-547.
7. Delle, F.G., Kwekkeboom, D.J., Van, C.E., et al,. (2012) ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology, 95, 74-87.
8. Koumarianou, A., Chatzellis, E., Boutzios, G., et al,. (2013) Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas. Endokrynologia Polska, 64, 60-72.
9. Kloppel, G., Rindi, G., Perren, A., et al,. (2010) The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Archiv, 456, 595-597.
10. Rindi, G., Kloppel, G., Alhman, H., et al,. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449, 395-401.
11. Modlin, I.M., Oberg, K., Chung, D.C., et al,. (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology, 9, 61-72.
12. Niederle, M.B., Hackl, M., Kaserer, K., et al,. (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine Related Cancer, 17, 909-918.
13. Rindi, G., Luinetti, O., Cornaggia, M., et al,. (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology, 104, 994-1006.
14. Fraenkel, M., Kim, M.K., Faggiano, A., et al,. (2012) Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Practice & Research. Clinical Gastroenterology, 26, 691-703.
15. Kidd, M., &, Gustafsson, B.I., (2012) Management of gastric carcinoids (neuroendocrine neoplasms). Current Gastroenterology Reports, 14, 467-472.
16. Ramage, J.K., Ahmed, A., Ardill, J., et al,. (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut, 61, 6-32.
17. Crosby, D.A., Donohoe, C.L., Fitzgerald, L., et al,. (2012) Gastric neuroendocrine tumours. Digestive Surgery, 29, 331-348.
18. Vannella, L., Lahner, E., &, Annibale, B., (2012) Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World Journal of Gastroenterology, 18, 1279-1285.
19. Vannella, L., Sbrozzi-Vanni, A., Lahner, E., et al,. (2011) Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Alimentary Pharmacology & Therapeutics, 33, 1361-1369.
20. Rugge, M., Correa, P., Dixon, M.F., et al,. (2002) Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Alimentary Pharmacology & Therapeutics, 16, 1249-1259.
21. Cockburn, A.N., Morgan, C.J., &, Genta, R.M., (2013) Neuroendocrine proliferations of the stomach: a pragmatic approach for the perplexed pathologist. Advances in Anatomic Pathology, 20, 148-157.
22. Burkitt, M.D., &, Pritchard, D.M., (2006) Review article: pathogenesis and management of gastric carcinoid tumours. Alimentary Pharmacology & Therapeutics, 24, 1305-1320.
23. Dockray, G.J., Varro, A., Dimaline, R., et al,. (2001) The gastrins: their production and biological activities. Annual Review of Physiology, 63, 119-139.
24. Annibale, B., Azzoni, C., Corleto, V.D., et al,. (2001) Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. European Journal of Gastroenterology & Hepatology, 13, 1449-1456.
25. Merola, E., Sbrozzi-Vanni, A., Panzuto, F., et al,. (2012) Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology, 95, 207-213.
26. Peracchi, M., Gebbia, C., Basilisco, G., et al,. (2005) Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. European Journal of Endocrinology, 152, 443-448.
27. Thomas, D., Tsolakis, A.V., Grozinsky-Glasberg, S., et al,. (2013) Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. European Journal of Endocrinology, 168, 185-193.
28. La Rosa, S., Inzani, F., Vanoli, A., et al,. (2011) Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Human Pathology, 42, 1373-1384.
29. Annibale, B., Lahner, E., &, Fave, G.D., (2011) Diagnosis and management of pernicious anemia. Current Gastroenterology Report, 13, 518-524.
30. Annibale, B., Di Giulio, E., Caruana, P., et al,. (2002) The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Alimentary Pharmacology & Therapeutics, 16, 1723-1731.
31. Borch, K., Ahren, B., Ahlman, H., et al,. (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Annals of Surgery, 242, 64-73.
32. Zorzetto, V., Maddalo, G., Basso, D., et al,. (2012) Immunotherapy for gastric premalignant lesions and cancer. Immunotherapy, 4, 587-599.
33. Schaffer, K., McBride, E.W., Beinborn, M., et al,. (1998) Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/ gastrin receptor. The Journal of Biological Chemistry, 273, 28779-28784.
34. Kagawa, J., Honda, S., Kodama, M., et al,. (2002) Enterocromaffin-like cell tumor induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter, 7, 390-397.
35. Hirschowitz, B.I., &, Haber, M.M., (2001) Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Alimentary Pharmacology & Therapeutics, 15, 87-103.
36. Jonsson, K.A., Strom, M., Bodemar, G., et al,. (1988) Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scandinavian Journal of Gastroenterology, 23, 433-441.
37. Armbrecht, U., Stockbrugger, R.W., Rode, J., et al,. (1990) Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut, 31, 1105-1109.
38. Borch, K., Renvall, H., Kullman, E., et al,. (1987) Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis. A prospective analysis of 11 cases. The American Journal of Surgical Pathology, 11, 435-444.
39. Kokkola, A., Sjoblom, S.M., Haapiainen, R., et al,. (1998) The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scandinavian Journal of Gastroenterology, 33, 88-92.
40. Lehtola, J., Karttunen, T., Krekela, I., et al,. (1985) Gastric carcinoids with minimal or no macroscopic lesion in patients with pernicious anemia. Hepato-Gastroenterology, 32, 72-76.
41. Sjoblom, S.M., Sipponen, P., &, Jarvinen, H., (1993) Gastroscopic follow up of pernicious anaemia patients. Gut, 34, 28-32.
42. Sjoblom, S.M., Sipponen, P., Miettinen, M., et al,. (1988) Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy, 20, 52-56.
43. Dakin, G.F., Warner, R.R., Pomp, A., et al,. (2006) Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. Journal of Surgical Oncology, 93, 368-372.
44. Hosokawa, O., Kaizaki, Y., Hattori, M., et al,. (2005) Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer, 8, 42-46.
45. Alexandraki, K.I., Nikolaou, A., Thomas, D., et al,. (2014) Are patients with autoimmune thyroid disease and autoimmune gastritis at risk for Gastric Neuroendocrine Tumours type 1? Clinical Endocrinology, 80, 685-690.
46. O'Toole, D., Delle, F.G., &, Jensen, R.T., (2012) Gastric and duodenal neuroendocrine tumours. Best Practice & Research. Clinical Gastroenterology, 26, 719-735.
47. Higham, A.D., Dimaline, R., Varro, A., et al,. (1998) Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology, 114, 817-822.
48. Delle, F.G., Capurso, G., Annibale, B., et al,. (2004) Gastric neuroendocrine tumors. Neuroendocrinology, 80 (Suppl 1), 16-19.
49. Grozinsky-Glasberg, S., Thomas, D., Strosberg, J.R., et al,. (2013) Metastatic type 1 gastric carcinoid: a real threat or just a myth? World Journal of Gastroenterology, 19, 8687-8695.
50. Gladdy, R.A., Strong, V.E., Coit, D., et al,. (2009) Defining surgical indications for type I gastric carcinoid tumor. Annals of Surgical Oncology, 16, 3154-3160.
51. Grozinsky-Glasberg, S., Kaltsas, G., Gur, C., et al,. (2008) Long-Acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. European Journal of Endocrinology, 159, 475-482.
52. Rindi, G., Paolotti, D., Fiocca, R., et al,. (2000) Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Archiv, 436, 217-223.
53. Tsolakis, A.V., Stridsberg, M., Grimelius, L., et al,. (2008) Ghrelin immunoreactive cells in gastric endocrine tumors and their relation to plasma ghrelin concentration. Journal of Clinical Gastroenterology, 42, 381-388.
54. Saund, M.S., Al Natour, R.H., Sharma, A.M., et al,. (2011) Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Annals of Surgical Oncology, 18, 2826-2832.
55. Jordan, P.H. Jr, Barroso, A., &, Sweeney, J., (2004) Gastric carcinoids in patients with hypergastrinemia. Journal of the American College of Surgeons, 199, 552-555.
56. Scherubl, H., Jensen, R.T., Cadiot, G., et al,. (2011) Management of early gastrointestinal neuroendocrine neoplasms. World Journal of Gastrointestinal Endoscopy, 3, 133-139.
57. Ichikawa, J., Tanabe, S., Koizumi, W., et al,. (2003) Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy, 35, 203-206.
58. Hirschowitz, B.I., Griffith, J., Pellegrin, D., et al,. (1992) Rapid regression of enterochromaffin like cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology, 102, 1409-1418.
59. Kern, S.E., Yardley, J.H., Lazenby, A.J., et al,. (1990) Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Modern Pathology, 3, 561-566.
60. Ahlman, H., Nilsson, O., &, Olausson, M., (2004) Interventional treatment of the carcinoid syndrome. Neuroendocrinology, 80 (Suppl 1), 67-73.
61. Wangberg, B., Grimelius, L., Granerus, G., et al,. (1990) The role of gastric resection in the management of multicentric argyrophil gastric carcinoids. Surgery, 108, 851-857.
62. Murugesan, S.V., Steele, I.A., Dimaline, R., et al,. (2013) Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours. European Journal of Gastroenterology & Hepatology, 25, 474-481.
63. Boutzios, G., Griniatsos, J., Dimitriou, N., et al,. (2013) The validity of current guidelines regarding surgical management of patients with gastric neuroendocrine neoplasms type 1: a report of a series of seven patients. Hormones (Athens, Greece), 12, 517-521.
64. Manfredi, S., Pagenault, M., de Lajarte-Thirouard, A.S., et al,. (2007) Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. European Journal of Gastroenterology & Hepatology, 19, 1021-1025.
65. Jianu, C.S., Fossmark, R., Syversen, U., et al,. (2011) Five-year follow-up of patients treated for 1 year with octreotide long-Acting release for enterochromaffin-like cell carcinoids. Scandinavia Journal of Gastroenterology, 46, 456-463.
66. Watson, S.A., Morris, T.M., Varro, A., et al,. (1999) A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut, 45, 812-817.
67. Fossmark, R., Sordal, O., Jianu, C.S., et al,. (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Alimentary Pharmacology & Therapeutics, 36, 1067-1075.
68. Ajani, J.A., Hecht, J.R., Ho, L., et al,. (2006) An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer, 106, 1908-1916.
69. Thomas, D., Alexandraki, K., Nikolaou, A., et al,. (2010) Primary hyperparathyroidism in patients with gastric carcinoid tumors type 1: an unusual coexistence. Neuroendocrinology, 92, 252-258.
70. Moore, A.R., Boyce, M., Steele, I.A., et al,. (2013) Netazepide, a gastrin receptor antagonist, normalizes tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS ONE, 8, e76462.